These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1066 related articles for article (PubMed ID: 34185297)

  • 21. The stromal compartments in pancreatic cancer: are there any therapeutic targets?
    Lunardi S; Muschel RJ; Brunner TB
    Cancer Lett; 2014 Feb; 343(2):147-55. PubMed ID: 24141189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type I collagen deletion in αSMA
    Chen Y; Kim J; Yang S; Wang H; Wu CJ; Sugimoto H; LeBleu VS; Kalluri R
    Cancer Cell; 2021 Apr; 39(4):548-565.e6. PubMed ID: 33667385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.
    Daniel SK; Sullivan KM; Labadie KP; Pillarisetty VG
    Clin Transl Med; 2019 Apr; 8(1):10. PubMed ID: 30931508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cells in pancreatic cancer stroma.
    Goulart MR; Stasinos K; Fincham REA; Delvecchio FR; Kocher HM
    World J Gastroenterol; 2021 Dec; 27(46):7956-7968. PubMed ID: 35046623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts.
    Pfeifer E; Burchell JM; Dazzi F; Sarker D; Beatson R
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives.
    Wu Y; Zhang C; Jiang K; Werner J; Bazhin AV; D'Haese JG
    Front Oncol; 2020; 10():621937. PubMed ID: 33520728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 3D pancreatic tumor model to study T cell infiltration.
    Mollica H; Teo YJ; Tan ASM; Tan DZM; Decuzzi P; Pavesi A; Adriani G
    Biomater Sci; 2021 Nov; 9(22):7420-7431. PubMed ID: 34706370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
    Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
    Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation.
    Xiao Y; Zhang H; Ma Q; Huang R; Lu J; Liang X; Liu X; Zhang Z; Yu L; Pang J; Zhou L; Liu T; Wu H; Liang Z
    Cancer Lett; 2019 Oct; 462():51-60. PubMed ID: 31352078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stromal deactivation by CSF1: a new feature of the aggressive pancreatic cancer microenvironment.
    Vera RE; Fernandez-Zapico ME
    EMBO Rep; 2020 May; 21(5):e50468. PubMed ID: 32329185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma.
    Joseph AM; Al Aiyan A; Al-Ramadi B; Singh SK; Kishore U
    Front Immunol; 2024; 15():1323198. PubMed ID: 38384463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dynamic interactions between the stroma, pancreatic stellate cells and pancreatic tumor development: Novel therapeutic targets.
    Farran B; Nagaraju GP
    Cytokine Growth Factor Rev; 2019 Aug; 48():11-23. PubMed ID: 31331827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
    Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
    ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal adenocarcinoma.
    Kong W; Liu Z; Sun M; Liu H; Kong C; Ma J; Wang R; Qian F
    Cancer Lett; 2022 Jul; 539():215718. PubMed ID: 35526650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma.
    Tang D; Wang D; Yuan Z; Xue X; Zhang Y; An Y; Chen J; Tu M; Lu Z; Wei J; Jiang K; Miao Y
    Int J Cancer; 2013 Mar; 132(5):993-1003. PubMed ID: 22777597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
    Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
    Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy.
    Saison-Ridinger M; DelGiorno KE; Zhang T; Kraus A; French R; Jaquish D; Tsui C; Erikson G; Spike BT; Shokhirev MN; Liddle C; Yu RT; Downes M; Evans RM; Saghatelian A; Lowy AM; Wahl GM
    PLoS One; 2017; 12(12):e0189051. PubMed ID: 29211796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic Stellate Cells: The Key Orchestrator of The Pancreatic Tumor Microenvironment.
    Thomas D; Radhakrishnan P
    Adv Exp Med Biol; 2020; 1234():57-70. PubMed ID: 32040855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.